Joanne Beck
Director/Board Member at ASTRIA THERAPEUTICS, INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Ford | M | 50 | 9 years | |
| Robert Funck | M | 62 | 37 years | |
| Jill Milne | M | 56 | 16 years | |
| Marc Dunoyer | M | 71 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Nicolas Koebel | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 years |
| Charles Rowland | M | 65 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Scott House | M | - | 34 years | |
| Noah Clauser | M | 51 | 13 years | |
| Ken Bate | M | 73 | 10 years | |
| David Elkins | M | 55 | 6 years | |
| John McCoy | M | 54 | 6 years | |
| Alicia Secor | F | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Simone Song | F | 59 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 years |
| James Geraghty | M | 69 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Kathryn Collins | F | - | 25 years | |
| Hubert Allen | M | 58 | 18 years | |
| Jon Ellis | M | 57 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Andrea Matthews | F | - | 10 years | |
| Hugh Cole | M | 59 | 5 years | |
| Claire Babineaux-Fontenot | F | 59 | 2 years | |
| Michelle Kumbier | F | 57 | 6 years | |
| Katherine Reynolds Kelly | F | 48 | 5 years | |
| Frederick Callori | M | 56 | 3 years | |
| Scott Leinenweber | M | - | 27 years | |
| Andrea Spezzi | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 years |
| Sally Blount | M | 62 | 13 years | |
| Bobby Gaspar | M | 60 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Michael O'Grady | M | 58 | 1 years | |
| Rajeev Venkayya | M | - |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Daniel Starks | M | 69 | 7 years | |
| Darren McDew | M | 63 | 5 years | |
| Melissa Brotz | F | - | - | |
| Randel Woodgrift | M | 62 | 12 years | |
| Gregg Lapointe | M | 65 | 5 years | |
| John Stratton | M | 63 | 7 years | |
| Michael Kishbauch | M | 75 | 8 years | |
| Michael Roman | M | 64 | 3 years | |
| Nancy McKinstry | F | 65 | 13 years | |
| Paola Gonzalez | F | 52 | 3 years | |
| Matt Roden | M | 53 | 5 years | |
| Philip Boudreau | M | 51 | 27 years | |
| Jonathan Violin | M | 49 | 3 years | |
| P. Joseph Campisi | M | - | 5 years | |
| Robert Alpern | M | 73 | 16 years | |
| Mary Moreland | F | 57 | 13 years | |
| Ann Li Lee | M | 63 | 6 years | |
| Christopher J Morabito | M | - | 2 years | |
| Karen Chayavirabood | F | - | - | |
| Claude Ramoni | M | - |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Jim Leffelman | M | - | - | |
| Kate Dyer | F | - | 4 years | |
| Andrew Komjathy | M | 61 | 5 years | |
| Gene Huang | M | - | - | |
| Andrea Wainer | F | - | 27 years | |
| Fulvio Mavilio | M | - | 2 years | |
| Ben Harshbarger | M | 55 | 4 years | |
| Yasuo Fujii | M | - | - | |
| Peter Honig | M | 67 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Jeffrey Galik | M | - | 5 years | |
| Lisa Earnhardt | F | 54 | 5 years | |
| Daniel Gesua Sive Salvadori | M | - | - | |
| Otello Stampacchia | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Vincent Ossipow | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| John M. Capek | M | 62 | 18 years | |
| Frank Thomas | M | 54 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Michael Powell | M | 69 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Stephen Knight | M | 63 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| John Ruesch | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Alles | M | 64 | 15 years | |
| Mark Rothera | M | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | 3 years |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Deirdre Cunnane | F | 59 | 4 years | |
| Robert Hugin | M | 69 | 19 years | |
| Jonathan Biller | M | 61 | 8 years | |
| Timothy J. Smith | M | - | - | |
| Peter Kellogg | M | 67 | 5 years | |
| Thomas Daniel | M | 69 | 10 years | |
| Scott Smith | M | 61 | 10 years | |
| Jay Backstrom | M | 69 | 11 years | |
| John Curnutte | M | 72 | 5 years | |
| Carrie Cox | F | 66 | 10 years | |
| Rupert Vessey | M | 59 | 4 years | |
| Thomas Perone | M | 59 | 12 years | |
| Brendan Delaney | M | 49 | 6 years | |
| Jacquelyn Sumer | F | 46 | 1 years | |
| Anne Dupraz-Poiseau | M | - | 6 years | |
| Michael Friedman | M | 80 | 8 years | |
| Michael Ross | M | 75 | 9 years | |
| Jean George | F | 66 | 9 years | |
| Michael Bonney | M | 65 | 4 years | |
| Elise T. Wang | F | 64 | - | |
| James J. Loughlin | M | 81 | 12 years | |
| Richard W. Barker | M | 75 | 7 years | |
| Burt Adelman | M | 71 | 5 years | |
| Michael D. Casey | M | 78 | 17 years | |
| Ernest Mario | M | 85 | 12 years | |
| Gilla Kaplan | M | 76 | 20 years | |
| Patricia Hemingway Hall | F | 71 | 1 years | |
| Robert Hershberg | M | 61 | 5 years | |
| Craig T. Basson | M | - |
Boston Pharmaceuticals, Inc.
 Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 85 | 85.00% |
| United Kingdom | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joanne Beck
- Personal Network